BRIEF — Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2 — Breast Cancer
Oct 13 (Reuters) — Prelude Therapeutics Incorporated: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate Kat6a Selective Degrader Prt13722 In Combination With Verzenio® And Inluriyo® In Patients With Hr+/her2- Breast Cancer Prelude Therapeutics Incorporated - Agreement Supports E